FDA Rejects Vanda's Hetlioz for Jet Lag—Shares Drop 12%
Vanda Pharmaceuticals stock falls in premarket trading after FDA denies Hetlioz approval for jet lag disorder, citing clinical trial design concerns despite positive efficacy data.
/ 1662 items
#XY↓
Morgan Stanley Changes Ratings on RCUS, NRIX, IOBT
Morgan Stanley updates biotech views, downgrading Arcus and IO Biotech while upgrading Nurix on stronger pipeline prospects.
Immuneering's Pancreatic Cancer Data Fails to Impress: Stock Plunges 23% Despite Survival Claims
Immuneering (IMRX) reports 64% survival rate for Atebimetinib in pancreatic cancer trial, but shares plunge 23% as investors remain unconvinced about cross-trial comparisons and competitive threats.
Globus Medical Stock Surges on Strong Q4 Results and Optimistic 2026 Outlook
Globus Medical (GMED) shares jump 9.4% in premarket trading after reporting preliminary Q4 sales of $823.2M, beating analyst estimates, with strong 2026 guidance signaling continued growth momentum.
AbbVie Denies Acquisition Talks with Revolution Medicines Despite WSJ Report
AbbVie denies reports of buying Revolution Medicines after Wall Street Journal claimed advanced talks.
Oppenheimer & H.C. Wainwright Bullish on LEGN, JBIO, CGEN
Oppenheimer and H.C. Wainwright start coverage on Legend Biotech, Jade Biosciences, and Compugen with bullish ratings and price targets, highlighting growth potential in CAR-T therapy, autoimmune, and immuno-oncology pipelines.